AGITG Clinical Trial research at ASCO

JeremyShapiro_with abstract_website

The final results of the AGITG ICECREAM  trial were presented at this year’s ASCO meeting in Chicago on 3 June, 2017. Many AGITG members and international colleagues participated in this important study, one of the first prospective trials to limit accrual to pre-defined molecular subsets of colorectal cancer.

Professor Jeremy Shapiro (pictured above) lead author commented that “the results of this important trial will add 2 further pieces to the complex colorectal treatment jigsaw”


Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA. | 2017 ASCO Annual Meeting Abstracts


Katrin_ website

INTEGRATE II was  also presented at ASCO in June in the progress session. Dr Katrin Sjoquist, INTEGRATE II Principal Investigator at St George Hospital (pictured above) commented:

“I was pleased to present the INTEGRATE II poster on behalf of the team at ASCO this year. The Trials In Progress session was a great opportunity to highlight this trial and we received overwhelmingly positive feedback”


Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).

SCOT results and IDEA meta-analysis presented @ASCO:
With contributions from AGITG members to the SCOT Study and the SCOT data included IDEA meta-analysis these two research projects in colorectal cancer were also presented at ASCO.


Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. | 2017 ASCO Annual Meeting Abstracts

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status